查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2165123

CAR-T細胞療法市場規模及預測（2021-2034年）

CAR-T Cell Therapy Market Size and Forecast (2021 - 2034)
出版日期: | 出版商: The Insight Partners | 英文 247 Pages | 訂單完成後即時交付

價格

根據我們最新發布的研究報告《CAR-T細胞療法市場預測：全球分析至2034年－按檢測器類型、終端用戶和地區分類》，該市場預計將從2025年的44.8億美元成長到2034年的193.1億美元，2026年至2034年的複合年成長率（CAGR）為17.6%。個人化CAR-T細胞療法正迅速崛起為高成長領域，醫療專業人員越來越需要針對各種骨髓惡性腫瘤、標靶抗原和治療方案（包括B細胞淋巴瘤、白血病和多發性骨髓瘤）量身定做的患者特異性治療策略。細胞工程、抗原標靶化、生產技術和治療個人化方面的進步正在推動下一代CAR-T療法的研發，這將提高療效和安全性，並擴大患者群體。

癌症，尤其是骨髓惡性腫瘤的日益加重，仍是推動CAR-T細胞療法需求成長的根本動力。對於進行性或復發性疾病患者，CAR-T療法具有最大的臨床價值，因為這些患者對傳統化療、標靶治療、移植或抗體療法的持續療效可能有限。已發表的臨床證據表明，CAR-T療法在某些復發或難治性B細胞白血病、淋巴瘤和多發性骨髓瘤患者中已達到約60-90%的完全緩解率，這表明該技術即使在難治性患者中也能帶來深度緩解。

淋巴瘤、白血病和多發性骨髓瘤的綜合需求帶來了特別重要的機遇，因為大量患者需要接受多線治療。儘管疾病復發和抗藥性不斷導致對創新療法的需求，但癌症診斷和存活率的提高正在增加能夠存活足夠長時間並需要後續治療的患者數量。此外，CAR-T療法正日益被視為一種潛在的根治性療法，而不僅僅是眾多治療方案之一，尤其是在單次給藥即可實現長期緩解的情況下。

北美、歐洲和亞太地區產能擴張和專業治療中心數量的增加進一步推動了市場成長。中國佔據尤為重要的地位；根據近期一項市場分析，到2026年，全球已確認的1908項CAR-T臨床試驗中，將有1006項在中國進行，凸顯了中國極其活躍的研發生態系統。

製藥公司加強投資力度，也正在加強開發平臺，加速商業化進程。此外，中國、印度、巴西和中東等新興市場醫療保健支出不斷成長，為低成本CAR-T產品的引入創造了機會。由於傳統的CAR-T療法在許多國家仍然價格昂貴且難以普及，因此開發本土化的療法尤其重要。

因此，癌症發病率上升、治療抗藥性增強、患者群體不斷擴大以及強大的臨床療效等因素預計將維持全球對 CAR-T 療法的需求。

進入CAR-T細胞療法市場的公司正著手進行大規模的市場重組。他們越來越關注透過全視野數位乳房攝影、數位乳房斷層合成、對比增強乳房X光攝影和影像重建技術的創新來提升檢測和診斷能力。例如，2026年7月，信達生物宣布與Spero達成獨家授權合約生物擁有權益的大中華區以外的IBI355的開發、研發、生產和商業化權利。 Spero公司預計將於2027年第二季啟動IBI355治療IgG4相關疾病（IgG4-RD）患者的第二期臨床試驗。同時，信達生物計畫於2027年初在中國啟動IBI355治療修格蘭氏症候群（SjD）的II期臨床試驗。此外，2026年6月，CARsgen Therapeutics Holdings Limited宣布，根據國家藥品監督管理局（NMPA）的通知，其自主研發的自體人源化Claudin 18.2 CAR-T細胞療法產品satri-cel已獲批用於治療至少接受過兩種既往療法但療效進行性的晚期胃癌/胃食道治療患者。 satri-cel是全球首個獲準用於治療固體癌的CAR- 新藥認證細胞療法產品。在進行市場分析和評估行業趨勢時，我們利用了來自 FDA、NCI、WHO、公司年報、投資者演示文稿、監管文件、官方產品文件、政府出版刊物、同行評審學術期刊、行業協會以及其他公開可獲取的醫療和醫療設備相關資訊來源的公開資訊。

CAR-T細胞療法市場的企業正採取以技術創新、產品開發、策略聯盟和地理擴張為核心的策略，以增強自身競爭力，滿足癌症治療機構不斷變化的需求。 CAR-T細胞療法技術在淋巴瘤、白血病和多發性骨髓瘤等適應症方面的進步至關重要，這得益於細胞工程、標靶抗原選擇、生產過程和新一代CAR-T構建體等方面的創新。本研究利用美國食品藥物管理局（FDA）、美國國家癌症研究所（NCI）、世界衛生組織（WHO）發布的數據、公司年報、投資者報告、產品資料、政府出版刊物、科學論文、臨床試驗註冊資訊以及其他公開的腫瘤學、細胞和基因治療資訊來源，對CAR-T細胞療法市場和行業趨勢進行了分析。

目錄

第1章執行摘要

第2章 CAR-T細胞療法市場展望

  • 概述
  • 價值鏈分析
  • 供應鏈分析
  • 波特五力分析
  • PEST分析
  • 人工智慧（AI）的影響
  • 產品或技術藍圖
  • 永續發展與ESG趨勢
  • 法律規範

第3章 競爭情勢

  • 企業標竿分析：依主要公司分類
  • 2025年市佔率分析：依主要公司分類
  • 市場集中度

第4章：CAR-T細胞療法市場：關鍵產業動態

  • 市場促進因素
    • CAR-T療法拓展至早期治療階段與新的適應症
    • 癌症負擔日益加重以及骨髓惡性腫瘤方面存在大量未滿足的需求
    • 細胞工程和製造技術的進步
  • 市場限制因素
    • 高昂的治療成本和製造成本
    • 複雜的製造和物流要求
    • 人們對該療法的毒性和長期安全性存在擔憂
  • 市場機遇
    • CAR-T療法治療固體癌
    • 拓展至自體免疫疾病領域
    • 新興市場和低成本CAR-T製造
  • 未來趨勢
    • 過渡到同種異體移植和現成的CAR-T療法
    • 體內CAR-T療法的出現
    • 多標靶和下一代CAR構建體的開發
  • 促進因素和抑制因素的影響

第5章 CAR-T細胞療法市場：全球市場分析

第6章 CAR-T細胞療法市場收入分析：以標靶抗原分類

  • CAR-T細胞療法市場預測與分析：以標靶抗原分類
    • CD19
    • BCMA

第7章：CAR-T細胞療法市場收入分析：依適應症分類

  • CAR-T細胞療法市場預測與分析：依適應症分類
    • 淋巴瘤
    • 白血病
    • 多發性骨髓瘤

第8章：CAR-T細胞療法市場收入分析：以最終用戶分類

  • CAR-T細胞療法市場預測與分析：依最終用戶分類
    • 醫院和專科診所
    • 門診手術中心
    • 其他

第9章 CAR-T細胞療法市場：區域分析

  • 北美洲
    • 標靶抗原
    • 適應症
    • 最終用戶
    • 美國市場
    • 加拿大市場
  • 歐洲
    • 英國市場
    • 德國市場
    • 法國市場
    • 義大利市場
    • 西班牙市場
    • 其他歐洲市場
  • 亞太地區
    • 中國市場
    • 日本市場
    • 印度市場
    • 澳洲市場
    • 韓國市場
    • 其他亞太市場
  • 世界其他地區

第10章 CAR-T細胞療法市場產業概況

第11章 CAR-T細胞療法市場：主要公司概況

  • Bristol-Myers Squibb Co
  • Novartis AG
  • Gilead Sciences Inc
  • Johnson & Johnson
  • JW（Cayman）Therapeutics Co Ltd
  • Innovent Biologics Inc
  • Autolus Therapeutics Plc
  • Shanghai Fosun Pharmaceutical Co Ltd
  • Immunoadoptive Cell Therapy Private Limited
  • CARsgen Therapeutics Holdings Limited

第12章附錄

Product Code: TIPRE00029935

According to our new research study on "CAR-T Cell Therapy Market Forecast to 2034 Global Analysis - by detector type, end users and geography," the market is anticipated to grow from US$ 4.48 billion in 2025 to US$ 19.31 billion by 2034, with a CAGR of 17.6% during 2026-2034. Personalized CAR-T cell therapy approaches are emerging as a high-growth category, with healthcare providers increasingly requiring patient-specific treatment strategies tailored to different hematological malignancies, target antigens, and lines of therapy, including B-cell lymphomas, leukemia, and multiple myeloma. Advances in cell engineering, antigen targeting, manufacturing technologies, and treatment personalization are supporting the development of next-generation CAR-T therapies with improved efficacy, safety, and broader patient applicability.

The growing burden of cancer, particularly hematological malignancies, remains a fundamental demand driver for CAR-T cell therapy. CAR-T has demonstrated its strongest clinical value in patients with aggressive or relapsed diseases for whom conventional chemotherapy, targeted medicines, transplantation, or antibody-based approaches may provide limited durable benefit. Published clinical evidence indicates that CAR-T therapies have achieved complete-remission rates of approximately 60-90% in selected relapsed/refractory B-cell leukemia, lymphoma, and multiple myeloma populations, illustrating the technology's ability to generate deep responses in difficult-to-treat patients.

The demand opportunity is particularly significant because lymphoma, leukemia, and multiple myeloma collectively represent a substantial population of patients requiring multiple lines of therapy. Disease relapse and treatment resistance continue to create a recurring need for innovative therapies, while improvements in cancer diagnosis and survival are increasing the number of patients living long enough to require subsequent treatment lines. CAR-T is also increasingly being positioned as a potentially definitive therapy rather than simply another sequential treatment, particularly where long-term remission can be achieved after a single infusion.

The market's growth is further supported by the expansion of manufacturing capacity and specialized treatment centers in North America, Europe, and Asia-Pacific. China has become particularly important, accounting for 1,006 of 1,908 CAR-T clinical trials identified globally in 2026 in one recent market analysis, highlighting the country's exceptionally active development ecosystem.

Increasing investment from pharmaceutical companies is also strengthening the pipeline and accelerating commercialization. Furthermore, growing healthcare expenditure in emerging markets such as China, India, Brazil, and the Middle East is creating opportunities to introduce lower-cost CAR-T products. The development of indigenous therapies is especially important because conventional CAR-T remains expensive and difficult to deliver in many countries.

Consequently, the combination of rising cancer prevalence, treatment resistance, expanding patient eligibility, and strong clinical efficacy is expected to sustain demand for CAR-T therapy globally.

The enterprises working in the CAR-T cell therapy Market have started Market consolidation efforts to a larger extent. More attention is being paid towards the enhancement of detection and imaging capabilities through full-field digital mammography, digital breast tomosynthesis, contrast-enhanced mammography, and image reconstruction innovations. For instance, in July 2026, Innovent Biologics, Inc. announced an exclusive license agreement for IBI355 (Spero R&D code: SP001), a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, research, manufacture, and commercialize IBI355 worldwide, excluding Greater China, where Innovent retains rights. Spero currently expects to advance IBI355 into a Phase 2 study in IgG4-RD patients in Q2 2027; Innovent expects to initiate a Phase 2 trial in China for SjD by early 2027. Similarly, in June 2026, CARsgen Therapeutics Holdings Limited announced that as informed by the National Medical Products Administration (NMPA), the New Drug Application (NDA) of satricabtagene autoleucel (satri-cel), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. Satri-cel is the world's first approved CAR T-cell therapy product for the treatment of solid tumors. The Market analysis and industry trends have been assessed with the help of publicly available information provided by the FDA, NCI, WHO, company annual reports, investor presentations, regulatory documents, official product documents, government publications, peer reviewed journals, industry associations and other publicly available health care and medical devices resources.

The players operating in the CAR-T cell therapy Market have adopted a strategy that involves technological innovations, product development, strategic alliances, and geographical expansion to improve their competitive position in line with the changing needs of cancer treatment providers. Much importance has been placed on advancements in CAR-T cell therapy technologies for applications such as lymphomas, leukemia, and multiple myeloma, leveraging innovations in cell engineering, target antigen selection, manufacturing processes, and next-generation CAR-T constructs. An analysis of the CAR-T cell therapy Market and industry trends was done through the use of publicly available data from the U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), World Health Organization (WHO), company annual reports, investor presentations, product literature, government publications, scientific publications, clinical trial registries, and other publicly available sources on oncology and cell and gene therapies.

Table Of Contents

1. Executive Summary

  • 1.1 Analyst Market Outlook
  • 1.2 Market Attractiveness

2. CAR-T Cell Therapy Market Landscape

  • 2.1 Overview
  • 2.2 Value Chain Analysis
    • 2.2.1 Raw Material Suppliers / Components
    • 2.2.2 Manufacturers / Process / Technology
    • 2.2.3 Distribution Landscape
    • 2.2.4 End User
    • 2.2.5 Level of Integration
  • 2.3 Supply Chain Analysis
    • 2.3.1 List of Manufacturers/Suppliers
    • 2.3.2 List of Potential Customers
  • 2.4 Porter's Five Force Analysis
    • 2.4.1 Bargaining Power of Suppliers: Moderate to High
    • 2.4.2 Bargaining Power of Buyers: High
    • 2.4.3 Threat of New Entrants: Moderate
    • 2.4.4 Threat of Substitutes: Moderate
    • 2.4.5 Competitive Rivalry: High
  • 2.5 PEST Analysis
  • 2.6 Impact of Artificial Intelligence (AI)
  • 2.7 Product or Technology Roadmap
  • 2.8 Sustainability and ESG Trends
    • 2.8.1 Environmental Trends
    • 2.8.2 Social Trends
    • 2.8.3 Governance Trends
  • 2.9 Regulatory Framework

3. Competitive Landscape

  • 3.1 Company Benchmarking by Key Players
  • 3.2 Market Share Analysis, 2025 - By Key Players
  • 3.3 Market Concentration

4. CAR-T Cell Therapy Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Expansion of CAR-T Therapy into Earlier Treatment Lines and New Indications
    • 4.1.2 Increasing Cancer Burden and High Unmet Need in Hematological Malignancies
    • 4.1.3 Advancement of Cell Engineering and Manufacturing Technologies
  • 4.2 Market Restraints
    • 4.2.1 High Treatment and Manufacturing Costs
    • 4.2.2 Complex Manufacturing and Logistical Requirements
    • 4.2.3 Treatment-Related Toxicity and Long-Term Safety Concerns
  • 4.3 Market Opportunities
    • 4.3.1 CAR-T Therapy for Solid Tumors
    • 4.3.2 Expansion into Autoimmune Diseases
    • 4.3.3 Emerging Markets and Lower-Cost CAR-T Manufacturing
  • 4.4 Future Trends
    • 4.4.1 Shift Toward Allogeneic and Off-the-Shelf CAR-T
    • 4.4.2 Emergence of In-Vivo CAR-T Therapy
    • 4.4.3 Development of Multi-Target and Next-Generation CAR Constructs
  • 4.5 Impact of Drivers and Restraints

5. CAR-T Cell Therapy Market - Global Market Analysis

  • 5.1 CAR-T Cell Therapy Market Revenue (US$ Million), 2021-2034
  • 5.2 CAR-T Cell Therapy Market Forecast and Analysis

6. CAR-T Cell Therapy Market Revenue Analysis -Targeted Antigen

  • 6.1 CAR-T Cell Therapy Market Forecasts and Analysis by Targeted Antigen
    • 6.1.1 CD19
      • 6.1.1.1 Overview
      • 6.1.1.2 CD19: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
    • 6.1.2 BCMA
      • 6.1.2.1 Overview
      • 6.1.2.2 BCMA: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)

7. CAR-T Cell Therapy Market Revenue Analysis -Indication

  • 7.1 CAR-T Cell Therapy Market Forecasts and Analysis by Indication
    • 7.1.1 Lymphomas
      • 7.1.1.1 Overview
      • 7.1.1.2 Lymphomas: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
    • 7.1.2 Leukemia
      • 7.1.2.1 Overview
      • 7.1.2.2 Leukemia: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
    • 7.1.3 Multiple Myeloma
      • 7.1.3.1 Overview
      • 7.1.3.2 Multiple Myeloma: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)

8. CAR-T Cell Therapy Market Revenue Analysis -End User

  • 8.1 CAR-T Cell Therapy Market Forecasts and Analysis by End User
    • 8.1.1 Hospitals and Specialty Clinics
      • 8.1.1.1 Overview
      • 8.1.1.2 Hospitals and Specialty Clinics: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
    • 8.1.2 Ambulatory Surgical Centers
      • 8.1.2.1 Overview
      • 8.1.2.2 Ambulatory Surgical Centers: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
    • 8.1.3 Others
      • 8.1.3.1 Overview
      • 8.1.3.2 Others: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)

9. CAR-T Cell Therapy Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America CAR-T Cell Therapy Market Overview
    • 9.1.2 North America: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.1.3 North America: CAR-T Cell Therapy Market- By Segmentation
      • 9.1.3.1 Targeted Antigen
      • 9.1.3.2 Indication
      • 9.1.3.3 End User
    • 9.1.4 North America: CAR-T Cell Therapy Market Breakdown by Countries
      • 9.1.4.1 United States Market
        • 9.1.4.1.1 United States: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.1.4.1.2 United States: CAR-T Cell Therapy Market- By Segmentation
          • 9.1.4.1.2.1 Targeted Antigen
          • 9.1.4.1.2.2 Indication
          • 9.1.4.1.2.3 End User
      • 9.1.4.2 Canada Market
        • 9.1.4.2.1 Canada: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.1.4.2.2 Canada: CAR-T Cell Therapy Market- By Segmentation
          • 9.1.4.2.2.1 Targeted Antigen
          • 9.1.4.2.2.2 Indication
          • 9.1.4.2.2.3 End User
  • 9.2 Europe
    • 9.2.1 Europe CAR-T Cell Therapy Market Overview
    • 9.2.2 Europe: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.2.3 Europe: CAR-T Cell Therapy Market- By Segmentation
      • 9.2.3.1 Targeted Antigen
      • 9.2.3.2 Indication
      • 9.2.3.3 End User
    • 9.2.4 Europe: CAR-T Cell Therapy Market Breakdown by Countries
      • 9.2.4.1 United Kingdom Market
        • 9.2.4.1.1 United Kingdom: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.1.2 United Kingdom: CAR-T Cell Therapy Market- By Segmentation
          • 9.2.4.1.2.1 Targeted Antigen
          • 9.2.4.1.2.2 Indication
          • 9.2.4.1.2.3 End User
      • 9.2.4.2 Germany Market
        • 9.2.4.2.1 Germany: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.2.2 Germany: CAR-T Cell Therapy Market- By Segmentation
          • 9.2.4.2.2.1 Targeted Antigen
          • 9.2.4.2.2.2 Indication
          • 9.2.4.2.2.3 End User
      • 9.2.4.3 France Market
        • 9.2.4.3.1 France: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.3.2 France: CAR-T Cell Therapy Market- By Segmentation
          • 9.2.4.3.2.1 Targeted Antigen
          • 9.2.4.3.2.2 Indication
          • 9.2.4.3.2.3 End User
      • 9.2.4.4 Italy Market
        • 9.2.4.4.1 Italy: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.4.2 Italy: CAR-T Cell Therapy Market- By Segmentation
          • 9.2.4.4.2.1 Targeted Antigen
          • 9.2.4.4.2.2 Indication
          • 9.2.4.4.2.3 End User
      • 9.2.4.5 Spain Market
        • 9.2.4.5.1 Spain: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.5.2 Spain: CAR-T Cell Therapy Market- By Segmentation
          • 9.2.4.5.2.1 Targeted Antigen
          • 9.2.4.5.2.2 Indication
          • 9.2.4.5.2.3 End User
      • 9.2.4.6 Rest of Europe Market
        • 9.2.4.6.1 Rest of Europe: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.2.4.6.2 Rest of Europe: CAR-T Cell Therapy Market- By Segmentation
          • 9.2.4.6.2.1 Targeted Antigen
          • 9.2.4.6.2.2 Indication
          • 9.2.4.6.2.3 End User
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific CAR-T Cell Therapy Market Overview
    • 9.3.2 Asia Pacific: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.3.3 Asia Pacific: CAR-T Cell Therapy Market- By Segmentation
      • 9.3.3.1 Targeted Antigen
      • 9.3.3.2 Indication
      • 9.3.3.3 End User
    • 9.3.4 Asia Pacific: CAR-T Cell Therapy Market Breakdown by Countries
      • 9.3.4.1 China Market
        • 9.3.4.1.1 China: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.1.2 China: CAR-T Cell Therapy Market- By Segmentation
          • 9.3.4.1.2.1 Targeted Antigen
          • 9.3.4.1.2.2 Indication
          • 9.3.4.1.2.3 End User
      • 9.3.4.2 Japan Market
        • 9.3.4.2.1 Japan: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.2.2 Japan: CAR-T Cell Therapy Market- By Segmentation
          • 9.3.4.2.2.1 Targeted Antigen
          • 9.3.4.2.2.2 Indication
          • 9.3.4.2.2.3 End User
      • 9.3.4.3 India Market
        • 9.3.4.3.1 India: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.3.2 India: CAR-T Cell Therapy Market- By Segmentation
          • 9.3.4.3.2.1 Targeted Antigen
          • 9.3.4.3.2.2 Indication
          • 9.3.4.3.2.3 End User
      • 9.3.4.4 Australia Market
        • 9.3.4.4.1 Australia: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.4.2 Australia: CAR-T Cell Therapy Market- By Segmentation
          • 9.3.4.4.2.1 Targeted Antigen
          • 9.3.4.4.2.2 Indication
          • 9.3.4.4.2.3 End User
      • 9.3.4.5 South Korea Market
        • 9.3.4.5.1 South Korea: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.5.2 South Korea: CAR-T Cell Therapy Market- By Segmentation
          • 9.3.4.5.2.1 Targeted Antigen
          • 9.3.4.5.2.2 Indication
          • 9.3.4.5.2.3 End User
      • 9.3.4.6 Rest of APAC Market
        • 9.3.4.6.1 Rest of APAC: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 9.3.4.6.2 Rest of APAC: CAR-T Cell Therapy Market- By Segmentation
          • 9.3.4.6.2.1 Targeted Antigen
          • 9.3.4.6.2.2 Indication
          • 9.3.4.6.2.3 End User
  • 9.4 Rest of World
    • 9.4.1 Rest of World CAR-T Cell Therapy Market Overview
    • 9.4.2 Rest of World: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 9.4.3 Rest of World: CAR-T Cell Therapy Market- By Segmentation
      • 9.4.3.1 Targeted Antigen
      • 9.4.3.2 Indication
      • 9.4.3.3 End User

10. CAR-T Cell Therapy Market Industry Landscape

11. CAR-T Cell Therapy Market - Key Company Profiles

  • 11.1 Bristol-Myers Squibb Co
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Novartis AG
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Gilead Sciences Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Johnson & Johnson
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 JW (Cayman) Therapeutics Co Ltd
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Innovent Biologics Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Autolus Therapeutics Plc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Shanghai Fosun Pharmaceutical Co Ltd
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Immunoadoptive Cell Therapy Private Limited
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CARsgen Therapeutics Holdings Limited
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 Glossary
  • 12.2 Research Methodology and Approach
    • 12.2.1 Secondary Research
    • 12.2.2 Primary Research
    • 12.2.3 Market Estimation Approach
      • 12.2.3.1 Supply Side Analysis
      • 12.2.3.2 Demand Side Analysis
    • 12.2.4 Research Assumptions and Limitations
    • 12.2.5 Currency Conversion
  • 12.3 About The Insight Partners
  • 12.4 Market Intelligence Cloud

List Of Tables

  • Table 1. List of Regulatory Bodies and Organizations
  • Table 2. Ease of Doing Business: Key Country Rankings
  • Table 3. Market Share Analysis, 2025 - By Key Players
  • Table 4. CAR-T Cell Therapy Market - Revenue, 2021-2025(US$ Million)
  • Table 5. CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034(US$ Million)
  • Table 6. North America: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 7. North America: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 8. North America: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 9. North America: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 10. North America: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 11. North America: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 12. United States: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 13. United States: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 14. United States: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 15. United States: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 16. United States: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 17. United States: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 18. Canada: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 19. Canada: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 20. Canada: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 21. Canada: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 22. Canada: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 23. Canada: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 24. Europe: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 25. Europe: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 26. Europe: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 27. Europe: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 28. Europe: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 29. Europe: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 30. United Kingdom: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 31. United Kingdom: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 32. United Kingdom: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 33. United Kingdom: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 34. United Kingdom: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 35. United Kingdom: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 36. Germany: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 37. Germany: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 38. Germany: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 39. Germany: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 40. Germany: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 41. Germany: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 42. France: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 43. France: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 44. France: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 45. France: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 46. France: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 47. France: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 48. Italy: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 49. Italy: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 50. Italy: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 51. Italy: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 52. Italy: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 53. Italy: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 54. Spain: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 55. Spain: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 56. Spain: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 57. Spain: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 58. Spain: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 59. Spain: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 60. Rest of Europe: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 61. Rest of Europe: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 62. Rest of Europe: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 63. Rest of Europe: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 64. Rest of Europe: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 65. Rest of Europe: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 66. Asia Pacific: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 67. Asia Pacific: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 68. Asia Pacific: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 69. Asia Pacific: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 70. Asia Pacific: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 71. Asia Pacific: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 72. China: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 73. China: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 74. China: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 75. China: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 76. China: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 77. China: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 78. Japan: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 79. Japan: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 80. Japan: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 81. Japan: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 82. Japan: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 83. Japan: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 84. India: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 85. India: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 86. India: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 87. India: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 88. India: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 89. India: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 90. Australia: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 91. Australia: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 92. Australia: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 93. Australia: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 94. Australia: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 95. Australia: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 96. South Korea: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 97. South Korea: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 98. South Korea: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 99. South Korea: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 100. South Korea: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 101. South Korea: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 102. Rest of APAC: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 103. Rest of APAC: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 104. Rest of APAC: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 105. Rest of APAC: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 106. Rest of APAC: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 107. Rest of APAC: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 108. Rest of World: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Targeted Antigen
  • Table 109. Rest of World: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Targeted Antigen
  • Table 110. Rest of World: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by Indication
  • Table 111. Rest of World: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by Indication
  • Table 112. Rest of World: CAR-T Cell Therapy Market - Revenue, 2021-2025 (US$ Million) - by End User
  • Table 113. Rest of World: CAR-T Cell Therapy Market - Revenue Forecast, 2026-2034 (US$ Million) - by End User
  • Table 114. Glossary - CAR-T Cell Therapy Market

List Of Figures

  • Figure 1. CAR-T Cell Therapy Market Segmentation
  • Figure 2. CAR-T Cell Therapy Market - Value Chain Analysis
  • Figure 3. Porter's Five Forces Analysis
  • Figure 4. Pest Analysis
  • Figure 5. CAR-T Cell Therapy Market - Key Industry Dynamics
  • Figure 6. Impact Analysis of Drivers and Restraints
  • Figure 7. CAR-T Cell Therapy Market Revenue (US$ Million), 2021-2034
  • Figure 8. CAR-T Cell Therapy Market Share (%) - by Targeted Antigen (2025 and 2034)
  • Figure 9. CD19: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 10. BCMA: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 11. CAR-T Cell Therapy Market Share (%) - by Indication (2025 and 2034)
  • Figure 12. Lymphomas: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 13. Leukemia: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 14. Multiple Myeloma: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 15. CAR-T Cell Therapy Market Share (%) - by End User (2025 and 2034)
  • Figure 16. Hospitals and Specialty Clinics: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 17. Ambulatory Surgical Centers: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 18. Others: CAR-T Cell Therapy Market -Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 19. CAR-T Cell Therapy Market Breakdown by Geography, 2025 and 2034
  • Figure 20. North America: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 21. North America: CAR-T Cell Therapy Market Breakdown by Key Countries, 2025 and 2034 (%)
  • Figure 22. United States: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 23. Canada: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 24. Europe: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 25. Europe: CAR-T Cell Therapy Market Breakdown by Key Countries, 2025 and 2034 (%)
  • Figure 26. United Kingdom: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 27. Germany: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 28. France: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 29. Italy: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 30. Spain: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 31. Rest of Europe: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 32. Asia Pacific: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 33. Asia Pacific: CAR-T Cell Therapy Market Breakdown by Key Countries, 2025 and 2034 (%)
  • Figure 34. China: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 35. Japan: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 36. India: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 37. Australia: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 38. South Korea: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 39. Rest of APAC: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 40. Rest of World: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • Figure 41. Bottom-Up Approach and Top-Down Approach